Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/3/969 |
| _version_ | 1797609490397265920 |
|---|---|
| author | Anne E. Levine Dominique Mark Laila Smith Hengqi B. Zheng David L. Suskind |
| author_facet | Anne E. Levine Dominique Mark Laila Smith Hengqi B. Zheng David L. Suskind |
| author_sort | Anne E. Levine |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease cohort where precision therapeutics can be applied. With the advent of rapid genetic sequencing platforms, these monogenic immunodeficiencies that cause inflammatory bowel disease are increasingly being identified. This subpopulation of IBD called very early onset inflammatory bowel disease (VEO-IBD) is defined by an age of onset of less than six years of age. Twenty percent of VEO-IBDs have an identifiable monogenic defect. The culprit genes are often involved in pro-inflammatory immune pathways, which represent potential avenues for targeted pharmacologic treatments. This review will provide an overview of the current state of disease-specific targeted therapies, as well as empiric treatment for undifferentiated causes of VEO-IBD. |
| first_indexed | 2024-03-11T06:02:04Z |
| format | Article |
| id | doaj.art-4f4334c45af24e819cc9847e3264e97a |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T06:02:04Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4f4334c45af24e819cc9847e3264e97a2023-11-17T13:16:57ZengMDPI AGPharmaceutics1999-49232023-03-0115396910.3390/pharmaceutics15030969Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel DiseasesAnne E. Levine0Dominique Mark1Laila Smith2Hengqi B. Zheng3David L. Suskind4Division of Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADepartment of Pharmacy, Seattle Children’s Hospital, Seattle, WA 98105, USADivision of Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADivision of Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USADivision of Gastroenterology, Seattle Children’s Hospital, Seattle, WA 98105, USAInflammatory bowel disease (IBD) is treated with a variety of immunomodulating and immunosuppressive therapies; however, for the majority of cases, these therapies are not targeted for specific disease phenotypes. Monogenic IBD with causative genetic defect is the exception and represents a disease cohort where precision therapeutics can be applied. With the advent of rapid genetic sequencing platforms, these monogenic immunodeficiencies that cause inflammatory bowel disease are increasingly being identified. This subpopulation of IBD called very early onset inflammatory bowel disease (VEO-IBD) is defined by an age of onset of less than six years of age. Twenty percent of VEO-IBDs have an identifiable monogenic defect. The culprit genes are often involved in pro-inflammatory immune pathways, which represent potential avenues for targeted pharmacologic treatments. This review will provide an overview of the current state of disease-specific targeted therapies, as well as empiric treatment for undifferentiated causes of VEO-IBD.https://www.mdpi.com/1999-4923/15/3/969very early onset inflammatory bowel disease (VEO-IBD)pharmacotherapymonogenic IBDmanagement |
| spellingShingle | Anne E. Levine Dominique Mark Laila Smith Hengqi B. Zheng David L. Suskind Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases Pharmaceutics very early onset inflammatory bowel disease (VEO-IBD) pharmacotherapy monogenic IBD management |
| title | Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases |
| title_full | Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases |
| title_fullStr | Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases |
| title_full_unstemmed | Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases |
| title_short | Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases |
| title_sort | pharmacologic management of monogenic and very early onset inflammatory bowel diseases |
| topic | very early onset inflammatory bowel disease (VEO-IBD) pharmacotherapy monogenic IBD management |
| url | https://www.mdpi.com/1999-4923/15/3/969 |
| work_keys_str_mv | AT anneelevine pharmacologicmanagementofmonogenicandveryearlyonsetinflammatoryboweldiseases AT dominiquemark pharmacologicmanagementofmonogenicandveryearlyonsetinflammatoryboweldiseases AT lailasmith pharmacologicmanagementofmonogenicandveryearlyonsetinflammatoryboweldiseases AT hengqibzheng pharmacologicmanagementofmonogenicandveryearlyonsetinflammatoryboweldiseases AT davidlsuskind pharmacologicmanagementofmonogenicandveryearlyonsetinflammatoryboweldiseases |